HB0025 for advanced solid tumors
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer (NSCLC) or endometrial cancer that cannot be surgically removed.
- You must not have had certain prior treatments, like immune checkpoint inhibitors combined with anti-vascular therapy, within 4 weeks before starting the study drug.
- You must have at least one measurable tumor that has not been treated with local therapy (or has clearly progressed after such treatment).
- You must be in generally good health (ECOG score 0 or 1) and have adequate organ function based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests a new drug called HB0025 combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before. It compares this combination to the current standard treatment (tislelizumab plus chemo) to see which works better.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
This trial compares a new drug, HB0025, combined with chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) as a first treatment for advanced squamous non-small cell lung cancer that cannot be removed by surgery or has spread. It aims to see if HB0025 is more effective and safe.
Hear when a new Advanced Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.